Firm believes it could lead to more accurate diagnostics and novel drug targets.
Health Discovery (HDC) filed a patent for U.S. and foreign protection for a newly discovered prostate cancer biomarker expression signature. “This new and exciting biomarker discovery could play a significant role in a more accurate diagnosis of prostate cancer as well as could provide important information for the development of new drug targets for the successful treatment of prostate cancer,” comments Herbert A. Fritsche, Ph.D., professor of laboratory medicine at the University of Texas M.D. Anderson Cancer Center and chairman of HDC’s science team.
“As medicine becomes increasingly personalized, discoveries of this nature could facilitate the development of new diagnostic tests and innovative treatments for prostate cancer,” adds Dr. Fritsche.
According to a recent paper published in the Journal of Urology by Tom Stamey, M.D., at Stanford University Medical Center and a member of HDC’s science team, the era of prostate specific antigen (PSA) is over because of its low accuracy rate in identifying clinically significant prostate cancer. Dr. Stamey believes that a more accurate test is needed to effectively detect this type of cancer.
“I firmly believe that this new prostate cancer biomarker discovery provides a significant opportunity towards providing a more accurate diagnosis of prostate cancer and important new information for identifying new therapeutic targets in treating this potentially devastating type of cancer,” states Stephen D. Barnhill, M.D., chairman & CEO.
